JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review of Mechanisms, Impact, and Advances in Management Strategies in Cancer-Related Pain

Berfinin Mahiba R J*, Felic S, Gopi B, Gnanaguru C

PharmaD Intern, JKK Munirajah Medical Research Foundation's Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalyam, Tamilnadu, India

Publication history: Received on 31st July; Revised on 8th August; Accepted on 18th August 2024

Article DOI: 10.69613/yzs0j215

Abstract: Cancer-related pain significantly impacts patients' quality of life and treatment outcomes, presenting a persistent challenge in oncology. The complex nature of cancer pain encompasses nociceptive, visceral, and neuropathic types, each with distinct characteristics and management requirements. Pain profoundly affects cognitive function, daily activities, and emotional well-being of cancer patients, often leading to decreased quality of life and treatment compliance. Current management strategies include both pharmacological and non-pharmacological approaches. Opioids, non-opioid analgesics, and adjuvant medications form the cornerstone of pharmacological interventions, while acupuncture and mind-body therapies show promise as complementary non-pharmacological methods. Recent advancements in pain assessment tools, such as digital pain diaries and wearable devices, offer improved monitoring capabilities and personalized pain management. Emerging therapies, including targeted immunotherapies and gene therapy approaches, represent new frontiers in cancer pain management. However, challenges persist in balancing effective pain relief with side effect minimization. The field is moving towards personalized, multimodal approaches that consider individual patient factors and pain mechanisms. Future research directions include developing novel analgesics, integrating artificial intelligence in pain assessment, and exploring personalized medicine strategies. Continued innovation and interdisciplinary collaboration are essential to enhance pain management and improve overall quality of life for cancer patients.

Keywords: Cancer pain; Quality of life; Neuropathic Pain; Immunotherapy; Gene Therapy; Personalized medicine; Multimodal Pain Management.

1. Introduction

Cancer remains one of the most challenging health issues of the 21st century, affecting millions of people worldwide [1]. As cancer incidence continues to rise with an aging population, so does the prevalence of cancer-related pain [2]. Pain is a common and often debilitating symptom experienced by cancer patients, significantly impacting their quality of life, treatment adherence, and overall outcomes [3]. Cancer-related pain is complex and multifaceted, arising from various sources including the tumor itself, metastases, and treatment-related side effects [4]. It can manifest as nociceptive, visceral, or neuropathic pain, each presenting unique challenges in management [5]. The impact of cancer pain extends beyond physical discomfort, affecting patients' cognitive function, emotional well-being, and daily activities [6]. Despite advancements in cancer treatment, pain management remains a critical aspect of comprehensive cancer care [7]. Traditional pharmacological approaches, primarily opioids and non-opioid analgesics, continue to play a central role in pain control [8]. However, concerns about opioid dependence and side effects have led to increased interest in alternative and complementary strategies [9].

Recent years have seen significant progress in our understanding of pain mechanisms, assessment tools, and novel therapeutic approaches [10]. From digital pain diaries to wearable devices, new technologies are enhancing pain monitoring and facilitating more personalized management strategies [11]. Emerging therapies, including targeted immunotherapies and gene therapy approaches, offer promising avenues for improved pain control [12]. The aim of this review is to provide a comprehensive overview of cancer-related pain, its mechanisms, impacts on patients, and current management strategies, while highlighting recent advancements and future directions in the field.

1.1. Types of Cancer Pain

Cancer-related pain is a complex and multifaceted phenomenon that can be categorized into several distinct types based on its underlying mechanisms and characteristics. Understanding these different types of pain is crucial for effective management and

* Corresponding author: Befinin Mahiba

treatment. The three main categories of cancer pain are nociceptive pain, visceral pain, and neuropathic pain, each with its unique features and challenges

1.1.1. Nociceptive pain

Nociceptive pain is the most common type of cancer-related pain, arising from the stimulation of nociceptors, which are specialized sensory neurons that detect potentially harmful stimuli [13]. In cancer patients, nociceptive pain can result from various sources, including tumor growth, inflammation, or tissue damage caused by cancer treatments.

Characteristics of nociceptive pain:

- Often described as sharp, aching, or throbbing
- Well-localized to the area of tissue damage or inflammation
- Typically responsive to opioid and non-opioid analgesics

Nociceptive pain can be further subdivided into somatic and visceral pain. Somatic nociceptive pain originates from skin, muscles, and bones. In cancer patients, this type of pain is commonly associated with bone metastases, which affect up to 70% of patients with advanced breast or prostate cancer [14]. The pain from bone metastases can be severe and debilitating, often described as a deep, constant ache that worsens with movement. Management of nociceptive pain typically involves a stepwise approach, following the World Health Organization's (WHO) pain ladder [15]. This approach begins with non-opioid analgesics like acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) for mild pain, progressing to weak opioids for moderate pain, and strong opioids for severe pain. Adjuvant medications, such as bisphosphonates for bone pain, may also be incorporated into the treatment regimen [16].

1.1.2. Visceral pain

Visceral pain is a subtype of nociceptive pain that originates from internal organs. In cancer patients, visceral pain often results from tumor invasion or compression of abdominal or thoracic viscera [17]. This type of pain is particularly common in cancers affecting organs such as the pancreas, liver, or gastrointestinal tract.

Characteristics of visceral pain:

- Often described as deep, squeezing, or pressure-like
- Typically poorly localized and may be referred to other areas
- Can be associated with autonomic symptoms such as nausea or sweating

Visceral pain can be challenging to manage due to its diffuse nature and the potential for referred pain. For example, pancreatic cancer pain may be felt in the upper abdomen and radiate to the back [18]. The complex innervation of visceral structures contributes to the difficulty in precisely localizing the pain source.

Management of visceral pain often requires a multimodal approach. While opioids remain the mainstay of treatment, adjuvant medications such as antispasmodics or anticholinergics may be beneficial, particularly for pain associated with bowel obstruction or spasm [19]. In some cases, interventional procedures like celiac plexus neurolysis may provide significant pain relief for upper abdominal visceral pain [20].

1.1.3. Neuropathic pain

Neuropathic pain results from damage or dysfunction of the nervous system itself. In cancer patients, this can occur due to direct tumor invasion of nerves, spinal cord compression, or as a side effect of cancer treatments such as chemotherapy or radiation therapy [21].

Characteristics of neuropathic pain:

- Often described as burning, shooting, or electric shock-like
- May be associated with sensory abnormalities like numbness or tingling
- Can be spontaneous or evoked by non-painful stimuli (allodynia)

Chemotherapy-induced peripheral neuropathy (CIPN) is a common form of neuropathic pain in cancer patients, affecting up to 68% of patients receiving neurotoxic chemotherapy [22]. CIPN typically presents as symmetric, distal sensory neuropathy, often described as a "stocking and glove" distribution of symptoms. Management of neuropathic pain can be challenging, as it often responds poorly to conventional analgesics. Treatment typically involves the use of adjuvant medications such as gabapentinoids (e.g., gabapentin, pregabalin), tricyclic antidepressants, or serotonin-norepinephrine reuptake inhibitors (SNRIs) [23]. In some cases, topical treatments like lidocaine patches or capsaicin cream may provide localized relief.

It's important to note that cancer patients often experience mixed pain syndromes, with elements of nociceptive, visceral, and neuropathic pain occurring simultaneously [24]. This complexity underscores the need for comprehensive pain assessment and individualized treatment strategies [13].

Table 1. Different types of cancer pain and their characteristics

Type of Pain	Description	Common Causes	Typical Characteristics
Nociceptive Pain	Pain caused by damage to body tissues	Tumor growth, inflammation, bone metastases	Sharp, aching, or throbbing pain
Visceral Pain	Pain originating from internal organs	Tumors affecting organs, metastases to abdominal cavity	Dull, cramping, or squeezing sensation
Neuropathic Pain	Pain caused by damage to nerves	Tumor compression of nerves, chemotherapy-induced neuropathy	Burning, tingling, or electric shock-like sensations

2. Mechanisms of Cancer Pain

Understanding the mechanisms underlying cancer pain is crucial for developing targeted and effective pain management strategies. Cancer pain arises from a complex interplay of multiple factors, including direct tumor effects, inflammatory processes, and neuroplastic changes in the nervous system.

2.1. Tumor-related mechanisms

Cancer cells can directly activate nociceptors through mechanical compression or by releasing various chemical mediators [25]. These mediators include prostaglandins, bradykinin, and cytokines, which sensitize nociceptors and lower their activation threshold. This process, known as peripheral sensitization, results in heightened pain sensitivity in the affected area [26]. Additionally, tumors can induce bone pain through multiple mechanisms. Osteoclast activation leads to bone resorption and the release of acid and growth factors, which further stimulate nociceptors [27]. The distortion of periosteum by tumor growth also contributes to severe bone pain.



Figure 1. Mechanisms of cancer pain

2.2. Inflammatory mechanisms

Cancer-related inflammation plays a significant role in pain generation and maintenance. The inflammatory soup produced by tumors and surrounding tissues contains numerous pro-nociceptive substances, including tumor necrosis factor-α (TNF-α),

interleukin-1β (IL-1β), and nerve growth factor (NGF) [28]. These inflammatory mediators not only activate nociceptors but also induce changes in gene expression, leading to long-term alterations in neuronal excitability.

2.3. Neuroplastic changes

Persistent nociceptive input from tumors can induce neuroplastic changes in the central nervous system, a phenomenon known as central sensitization [29]. This process involves alterations in synaptic transmission and intracellular signaling cascades within the spinal cord and brain, leading to amplified pain processing. Key mechanisms of central sensitization include:

- Increased excitability of dorsal horn neurons
- Expansion of receptive fields
- Activation of normally silent synapses
- Descending facilitation from brainstem nuclei

These changes can result in pain hypersensitivity, allodynia, and the spread of pain beyond the original site of injury.

2.4. Neuropathic mechanisms

In cases of neuropathic cancer pain, additional mechanisms come into play. Direct tumor invasion or compression of nerves can lead to axonal damage and demyelination [30]. This results in ectopic activity in damaged neurons and altered expression of ion channels, contributing to spontaneous pain and hypersensitivity. Chemotherapy-induced neuropathic pain involves distinct mechanisms, including mitochondrial dysfunction, oxidative stress, and alterations in ion channel function [31]. For example, platinum-based chemotherapies can accumulate in dorsal root ganglia, leading to DNA damage and neuronal apoptosis.

2.5. Immune system involvement

Recent research has highlighted the crucial role of neuroimmune interactions in cancer pain [32]. Activation of glial cells, particularly microglia and astrocytes, in the spinal cord and brain contributes to the maintenance of chronic pain states. These activated glial cells release pro-inflammatory cytokines and chemokines, further amplifying pain signaling.

2.6. Genetic factors

Genetic variations can influence an individual's susceptibility to cancer pain and their response to analgesic treatments [33]. Polymorphisms in genes encoding opioid receptors, catechol-O-methyltransferase (COMT), and various cytokines have been associated with differences in pain perception and analgesic efficacy.

2.7. Epigenetic modifications

Epigenetic changes, such as DNA methylation and histone modifications, have emerged as important mechanisms in the development and maintenance of chronic pain states [34]. These modifications can alter gene expression patterns in nociceptive pathways, potentially contributing to the transition from acute to chronic pain in cancer patients.

2.8. Alterations in descending pain modulation

Dysfunction in descending pain modulatory systems, which normally help to inhibit pain signaling, can contribute to the persistence of cancer pain [35]. Imbalances between descending inhibition and facilitation from brainstem nuclei can lead to enhanced pain processing at the spinal level. Understanding these complex and interrelated mechanisms of cancer pain is essential for developing targeted therapeutic approaches. For example, recognition of the role of NGF in cancer pain has led to the development of anti-NGF monoclonal antibodies as potential analgesic agents [36]. Similarly, insights into neuroimmune interactions have spurred interest in glial cell modulators as novel pain therapeutics.

3. Impact of Cancer Pain on Quality of Life

Cancer-related pain significantly affects patients' quality of life, impacting various aspects of their daily functioning, cognitive abilities, and emotional well-being. Understanding these wide-ranging effects is crucial for developing comprehensive pain management strategies that address not only the physical aspects of pain but also its broader impact on patients' lives.

3.1. Functional Impairment

Cancer pain can lead to substantial functional impairment, limiting patients' ability to perform daily activities and maintain their independence. This impairment can manifest in several ways:

3.1.1. Physical Activity Limitations

Patients with cancer pain often experience reduced mobility and physical function [38]. This can range from difficulty with basic activities of daily living (ADLs) such as bathing, dressing, and eating, to more complex instrumental activities of daily living (IADLs) like housework, shopping, and managing finances. A study by van den Beuken-van Everdingen et al. found that 67% of cancer patients reported pain-related interference with daily activities [39].

3.1.2. Sleep Disturbances

Pain can significantly disrupt sleep patterns, leading to insomnia, frequent night awakenings, and poor sleep quality [40]. Chronic sleep disturbances can, in turn, exacerbate pain perception, creating a vicious cycle. A meta-analysis by Sharma et al. reported that up to 72% of cancer patients experience sleep disturbances, with pain being a major contributing factor [41].

3.1.3. Reduced Work Productivity

Cancer pain can impact patients' ability to work, leading to decreased productivity, increased absenteeism, and even job loss [42]. This not only affects patients' financial stability but can also impact their sense of purpose and self-esteem.

3.1.4. Social Isolation

Pain-related functional limitations can lead to reduced social interactions and participation in leisure activities [43]. This social withdrawal can further contribute to psychological distress and diminished quality of life.

3.1.5. Sexual Dysfunction

Cancer pain, particularly in pelvic or genitourinary cancers, can significantly impact sexual function and intimacy [44]. This aspect of functional impairment is often underreported and undertreated, despite its importance in overall quality of life.

3.2. Cognitive Effects

Cancer pain can have profound effects on cognitive function, impacting various domains of mental processing. These cognitive effects, often referred to as "cancer-related cognitive impairment" (CRCI) or "chemo brain," can persist even after pain is adequately controlled.

3.2.1. Attention and Concentration

Pain can act as a constant distractor, impairing patients' ability to focus and sustain attention [45]. This can affect performance in both daily tasks and more complex cognitive activities.

3.2.2. Memory Deficits

Both working memory and long-term memory can be affected by cancer pain [46]. Patients may struggle with remembering appointments, medication schedules, or even recent conversations.

3.2.3. Executive Function

Higher-order cognitive processes such as planning, problem-solving, and decision-making can be compromised in patients with cancer pain [47]. This can impact patients' ability to manage their treatment regimens and make informed decisions about their care.

3.2.4. Processing Speed

Cancer pain has been associated with slowed cognitive processing speed, affecting patients' ability to quickly process information and respond to their environment [48].

3.2.5. Language and Communication

Some patients with cancer pain may experience difficulties with verbal fluency and communication, although this is less commonly reported than other cognitive effects [49].

The mechanisms underlying these cognitive effects are multifaceted and may involve:

- Direct effects of pain on brain function and structure
- Shared neural pathways between pain processing and cognitive functions
- Side effects of pain medications, particularly opioids
- Sleep disturbances secondary to pain

- Psychological factors such as depression and anxiety

3.3. Psychological and Emotional Impact

The psychological and emotional impact of cancer pain is profound and multifaceted, often interacting with and exacerbating the physical aspects of pain.

3.3.1. Depression

Cancer pain is strongly associated with increased rates of depression [50]. A meta-analysis by Krebber et al. found that the prevalence of depression in cancer patients ranges from 8% to 24%, with higher rates in patients experiencing pain [51]. Depression can, in turn, lower pain thresholds and reduce patients' ability to cope with pain.

3.3.2. Anxiety

Pain-related anxiety is common among cancer patients, manifesting as fear of pain exacerbation, anticipatory anxiety about medical procedures, and worry about pain signaling disease progression [52]. This anxiety can lead to avoidance behaviors and increased pain catastrophizing.

3.3.3. Mood Disturbances

Cancer pain can lead to irritability, mood swings, and emotional lability [53]. These mood disturbances can strain relationships with family members and caregivers, further impacting quality of life.

3.3.4. Fear and Uncertainty

Uncontrolled pain can intensify fears about disease progression and death [54]. This existential distress can significantly impact patients' overall well-being and their ability to engage in meaningful activities.

3.3.5. Loss of Control and Helplessness

Persistent pain can lead to feelings of helplessness and loss of control over one's body and life circumstances [55]. This can undermine patients' sense of self-efficacy and their ability to actively participate in their care.

3.3.6. Social Relationships

Pain can strain social relationships, leading to feelings of isolation and reduced social support [56]. Patients may withdraw from social activities due to pain or fear of being a burden to others.

3.3.7. Body Image and Self-esteem

Cancer pain, particularly when associated with visible physical changes or functional limitations, can negatively impact body image and self-esteem [57].

3.3.8. Spiritual and Existential Distress

For some patients, persistent pain can lead to questioning of spiritual beliefs or life's meaning, contributing to existential distress [58]. The psychological impact of cancer pain is not limited to patients alone but extends to their caregivers and family members. Caregiver distress and burnout are common in families dealing with cancer pain, highlighting the need for comprehensive support systems [59]

4. Current Pain Management Strategies

Effective management of cancer pain requires a multidisciplinary approach, combining pharmacological and non-pharmacological interventions tailored to individual patient needs. The goal is to provide adequate pain relief while minimizing side effects and maintaining the best possible quality of life.

4.1. Pharmacological Approaches

Pharmacological management of cancer pain typically follows the World Health Organization (WHO) analgesic ladder, which recommends a stepwise approach based on pain intensity [60].

4.1.1. Opioids

Opioids remain the cornerstone of cancer pain management, particularly for moderate to severe pain. They act by binding to opioid receptors in the central and peripheral nervous system, modulating pain perception.

Types of Opioids:

- Weak opioids: Codeine, tramadol
- Strong opioids: Morphine, oxycodone, hydromorphone, fentanyl, methadone

Administration Routes:

- Oral: Preferred route for long-term management
- Transdermal: Useful for stable pain, particularly in patients unable to take oral medications
- Intravenous/Subcutaneous: For rapid titration or in patients unable to take oral medications
- Intraspinal: For refractory pain or intolerable side effects with systemic administration

Opioid Selection and Titration: Opioid selection should be individualized based on pain intensity, patient characteristics, and previous opioid exposure [61]. Titration should aim to balance pain relief with side effects, starting with low doses and increasing gradually.

Side Effects and Management: Common side effects include constipation, nausea, sedation, and respiratory depression [62]. Proactive management of side effects, particularly constipation, is crucial. Opioid rotation may be considered in cases of intolerable side effects or inadequate pain relief.

Opioid-Induced Hyperalgesia: Prolonged opioid use can paradoxically lead to increased pain sensitivity in some patients [63]. Recognition of this phenomenon is important for appropriate management, which may involve opioid dose reduction or rotation.

Concerns and Challenges

- Opioid tolerance and physical dependence
- Risk of opioid use disorder, although this risk is generally lower in cancer patients than in the general population [64]
- Regulatory barriers and opiophobia among healthcare providers and patients

Despite these challenges, opioids remain essential in cancer pain management when used appropriately. Recent guidelines emphasize the importance of safe opioid prescribing practices, including risk assessment, patient education, and close monitoring [65].

4.1.2. Non-opioid Analgesics

Non-opioid analgesics play a crucial role in cancer pain management, either as sole agents for mild pain or as adjuncts to opioids for more severe pain.

Acetaminophen (Paracetamol)

- Mechanism: Centrally acting analgesic and antipyretic
- Uses: Mild to moderate pain, often in combination with opioids
- Considerations: Hepatotoxicity risk at high doses or in patients with liver dysfunction [66]

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

- Mechanism: Inhibition of cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis
- Types: Non-selective (e.g., ibuprofen, naproxen) and COX-2 selective (e.g., celecoxib)
- Uses: Particularly effective for inflammatory pain, such as bone metastases
- Considerations: Risk of gastrointestinal, renal, and cardiovascular side effects, especially with long-term use [67]

Topical Analgesics

- Examples: Lidocaine patches, capsaicin cream
- Uses: Localized neuropathic pain or well-defined areas of nociceptive pain
- Advantages: Minimal systemic absorption, reduced risk of drug interactions [68]

Cannabinoids

- Mechanism: Activation of cannabinoid receptors in the nervous system
- Uses: Emerging evidence for efficacy in cancer-related pain, particularly in combination with opioids
- Considerations: Variability in legal status, limited long-term safety data in cancer patients [69]

Ketamine (Sub-anesthetic doses)

- Mechanism: NMDA receptor antagonist
- Uses: Refractory cancer pain, opioid-induced hyperalgesia
- Considerations: Potential for psychomimetic side effects, limited evidence for long-term use [70]

4.2. Non-pharmacological Interventions

Non-pharmacological interventions play a crucial role in comprehensive cancer pain management. These approaches can complement pharmacological treatments, potentially reducing the need for medications and their associated side effects. Non-pharmacological interventions can also address the multidimensional nature of cancer pain, targeting not only physical symptoms but also psychological and emotional aspects.

4.2.1. Acupuncture

Acupuncture, an ancient Chinese healing practice, has gained recognition in Western medicine for its potential benefits in managing cancer-related symptoms, including pain [71].

Mechanism of Action

The exact mechanisms by which acupuncture alleviates pain are not fully understood but are thought to involve:

- Stimulation of endogenous opioid release
- Modulation of the autonomic nervous system
- Alteration of neurotransmitter levels
- Anti-inflammatory effects

Evidence in Cancer Pain

Several studies have investigated the efficacy of acupuncture in cancer pain management

- A systematic review by Chiu et al. (2017) found that acupuncture was associated with reduced pain intensity and analgesic consumption in cancer patients [72].
- A randomized controlled trial by Mao et al. (2014) demonstrated that electroacupuncture significantly reduced joint pain in women with breast cancer taking aromatase inhibitors [73].
- A meta-analysis by He et al. (2020) suggested that acupuncture may be effective for chemotherapy-induced peripheral neuropathy [74].

Implementation Considerations

- Safety: Generally considered safe when performed by trained practitioners, with minimal risk of serious adverse events.
- Integration: Can be easily integrated into conventional cancer care settings.
- Patient Selection: May be particularly beneficial for patients seeking non-pharmacological options or those experiencing medication side effects.

Limitations

- Variability in treatment protocols and practitioner expertise can affect outcomes.
- Some studies have methodological limitations, and larger, well-designed trials are needed to strengthen the evidence base.

4.2.2. Mind-body Therapies

Mind-body therapies encompass a range of techniques that leverage the connection between the mind, body, and behavior to promote relaxation, reduce stress, and alleviate pain [75].

Key Mind-body Therapies:

1. Meditation and Mindfulness-Based Stress Reduction (MBSR)

    - Mechanism: Enhances pain coping skills, reduces anxiety and depression, may alter pain perception.
    - Evidence: A meta-analysis by Zhang et al. (2016) found that MBSR significantly reduced pain intensity and improved quality of life in cancer patients [76].

2. Guided Imagery

    - Mechanism: Uses mental visualization to promote relaxation and shift focus away from pain.
    - Evidence: A study by Charalambous et al. (2016) demonstrated that guided imagery reduced pain and fatigue in breast cancer patients undergoing chemotherapy [77].

3. Progressive Muscle Relaxation

    - Mechanism: Involves systematically tensing and relaxing muscle groups to reduce physical tension and associated pain.
    - Evidence: A randomized controlled trial by Özveren and Uçar (2020) found that progressive muscle relaxation significantly reduced pain intensity in cancer patients [78].

4. Hypnosis

    - Mechanism: Induces a state of focused attention and heightened suggestibility, potentially altering pain perception.
    - Evidence: A systematic review by Cramer et al. (2015) suggested that hypnosis may be effective for procedural pain in cancer patients [79].

5. Cognitive Behavioral Therapy (CBT)

    - Mechanism: Addresses maladaptive thoughts and behaviors related to pain, enhancing coping strategies.
    - Evidence: A meta-analysis by Syrjala et al. (2014) found that CBT was effective in reducing cancer pain intensity and improving functional outcomes [80].

Implementation Considerations

- Cost-effective and can be self-administered after initial training.
- Can be delivered in various formats, including in-person, group sessions, or digital platforms.
- May be particularly beneficial for addressing the psychological components of cancer pain.

Limitations

- Efficacy may vary depending on patient engagement and practice consistency.
- Some techniques may require specialized training for healthcare providers.

4.2.3. Physical Therapy and Exercise

Physical therapy and exercise interventions are increasingly recognized as important components of cancer pain management, offering benefits beyond pain relief [81].

Types of Interventions

1. Therapeutic Exercise:
    - Includes aerobic, strength training, and flexibility exercises.
    - Benefits: Improves physical function, reduces fatigue, and may alleviate pain through various mechanisms.
2. Manual Therapy:
    - Techniques such as massage, joint mobilization, and myofascial release.
    - Benefits: Can help reduce muscle tension, improve circulation, and provide localized pain relief.
3. Transcutaneous Electrical Nerve Stimulation (TENS):
    - Application of low-voltage electrical currents to the skin.
    - Mechanism: May stimulate endogenous opioid release and modulate pain signaling.

Evidence in Cancer Pain

- A systematic review by Nakano et al. (2020) found that exercise interventions were effective in reducing cancer-related pain and improving quality of life [82].
- A randomized controlled trial by Cantarero-Villanueva et al. (2013) demonstrated that a multimodal physical therapy program reduced pain and improved function in breast cancer survivors [83].
- A meta-analysis by Hurlow et al. (2012) suggested that TENS may be effective for cancer bone pain, although more high-quality studies are needed [84].

Implementation Considerations

- Individualization: Exercise and physical therapy programs should be tailored to each patient's physical condition, cancer type, and treatment status.
- Safety: Proper screening and monitoring are essential, particularly for patients with bone metastases or other cancer-related complications.
- Multidisciplinary Approach: Collaboration between physical therapists, oncologists, and pain specialists is crucial for optimal outcomes.

Limitations

- Physical limitations or severe pain may restrict participation in some interventions.
- Accessibility to specialized oncology rehabilitation services may be limited in some areas

Table 2. Current pain management strategies

Approach	Examples	Advantages	Limitations
Pharmacological (Opioids)	Morphine, Oxycodone, Fentanyl	Effective for moderate to severe pain	Risk of dependence, side effects
Pharmacological (Non-opioid Analgesics)	NSAIDs, Acetaminophen	Fewer side effects than opioids	May not be sufficient for severe pain
Pharmacological (Adjuvant Medications)	Antidepressants, Anticonvulsants	Effective for neuropathic pain	May have psychiatric side effects
Non-pharmacological (Acupuncture)	Traditional Chinese acupuncture	No drug interactions, minimal side effects	Efficacy varies, may require multiple sessions
Non-pharmacological (Mind-body Therapies)	Meditation, Yoga, Cognitive Behavioral Therapy	Improves coping, reduces stress	May not provide immediate pain relief
Non-pharmacological (Physical Therapy)	Exercise, Manual therapy	Improves function, reduces pain	May be limited by patient's physical condition

5. Advancements in Pain Assessment Tools

Accurate pain assessment is fundamental to effective pain management. Recent technological advancements have led to the development of novel tools that offer more comprehensive and real-time pain assessment.

5.1. Digital Pain Diaries

Digital pain diaries have emerged as a valuable tool for capturing detailed, longitudinal data on patients' pain experiences [85].

5.1.1. Key Features

- Real-time data entry: Allows patients to record pain intensity, location, and characteristics as they occur.
- Customizable prompts: Can include questions about pain interference, medication use, and associated symptoms.
- Integration with other data: Some platforms can incorporate data from wearable devices or electronic health records.

5.1.2. Benefits

- Improved Accuracy: Reduces recall bias associated with retrospective pain reporting.
- Enhanced Communication: Facilitates more informed discussions between patients and healthcare providers.
- Pattern Recognition: Enables identification of temporal patterns and pain triggers.
- Treatment Monitoring: Allows for more precise evaluation of treatment efficacy and side effects.

5.1.3. Evidence

- A study by Sundararaman et al. (2017) found that digital pain diaries improved pain documentation and patient-provider communication in cancer patients [86].
- Research by Jonassaint et al. (2018) demonstrated that mobile pain reporting led to earlier pain interventions and improved pain control in sickle cell disease patients [87].

5.1.4. Implementation Considerations

- User-friendly interface design is crucial for patient engagement and adherence.
- Data security and privacy measures must be robust to protect sensitive health information.
- Integration with existing electronic health record systems can streamline clinical workflows.

5.1.5. Limitations

- Requires patient access to and familiarity with digital devices.
- Potential for data overload if not properly managed and interpreted.

5.2. Wearable Devices for Pain Monitoring

Wearable technology offers the potential for continuous, objective pain monitoring, complementing subjective patient-reported measures [88].

5.2.1. Types of Wearable Pain Monitoring Devices

Biometric Sensors

- Measure physiological parameters associated with pain, such as heart rate variability, skin conductance, and muscle tension.
- Example: The PMD-200 pain monitoring device, which analyzes multiple physiological parameters to provide a nociception index [89].

Motion Sensors

- Track physical activity and movement patterns, which can be indicators of pain-related functional impairment.
- Example: Accelerometers integrated into smartwatches or dedicated devices.

Pressure Sensors

- Measure applied pressure or force, potentially useful for assessing pain related to touch or movement.
- Example: Smart textiles with embedded pressure sensors.

Benefits:

- Continuous Monitoring: Provides a more comprehensive picture of pain patterns over time.
- Objective Data: Offers physiological correlates of pain, complementing subjective reports.
- Early Detection: May identify pain exacerbations or treatment effects before they become clinically apparent.
- Personalized Treatment: Enables more tailored and timely pain management interventions.

Evidence

- A study by Huang et al. (2021) demonstrated that wearable sensors could detect pain-related behaviors in cancer patients with high accuracy [90].
- Research by Darnall et al. (2020) showed that a digital pain management program incorporating wearable devices led to significant reductions in pain intensity and opioid use [91].

Implementation Considerations

- Algorithm Development: Sophisticated algorithms are needed to interpret complex biometric data and correlate it with pain experiences.
- Validation: Rigorous clinical validation is essential to establish the reliability and validity of wearable pain monitoring devices.
- Patient Education: Users must be properly trained in device use and data interpretation.

Limitations

- Current technologies may not capture all aspects of the pain experience, particularly the emotional and cognitive components.
- Potential for false positives or negatives, as physiological changes can be influenced by factors other than pain.
- Cost and accessibility may limit widespread adoption

6. Conclusion

Cancer pain management remains a critical challenge in oncology, demanding a multidisciplinary approach that combines pharmacological and non-pharmacological interventions. While opioids continue to play a central role, judicious use and careful monitoring are essential to balance efficacy with safety. The integration of complementary therapies like acupuncture, mind-body techniques, and physical therapy offers promising avenues for comprehensive pain relief and improved quality of life. Emerging technologies, including digital pain diaries and wearable devices, are revolutionizing pain assessment, enabling more personalized and timely interventions. As research progresses, the focus on developing targeted therapies, refining assessment tools, and implementing evidence-based practices will be crucial in advancing cancer pain management. Ultimately, the goal remains to alleviate suffering and enhance the overall well-being of cancer patients throughout their journey.

References

[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.

[2] van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage. 2016;51(6):1070-1090.e9.

[3] Greco MT, Roberto A, Corli O, Deandrea S, Bandieri E, Cavuto S, et al. Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. J Clin Oncol. 2014;32(36):4149-54.

[4] Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv166-iv191.

[5] Paice JA, Portenoy R, Lacchetti C, Campbell T, Cheville A, Citron M, et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(27):3325-45.

[6] World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. Geneva: World Health Organization; 2018.

[7] Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58-68.

[8] Wiffen PJ, Wee B, Derry S, Bell RF, Moore RA. Opioids for cancer pain - an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;7(7):CD012592.

[9] Portenoy RK, Ahmed E. Principles of opioid use in cancer pain. J Clin Oncol. 2014;32(16):1662-70.

[10] Schmidt-Hansen M, Bennett MI, Arnold S, Bromham N, Hilgart JS. Oxycodone for cancer-related pain. Cochrane Database Syst Rev. 2017;8(8):CD003870.

[11] Wiffen PJ, Derry S, Moore RA. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database Syst Rev. 2014;(5):CD011056.

[12] Kress HG, Koch ED, Kosturski H, Steup A, Karcher K, Lange B, et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician. 2014;17(4):329-43.

[13] Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Verna L, et al. Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin. 2012;28(11):1775-9.

[14] McNicol E, Strassels SA, Goudas L, Lau J, Carr DB. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev. 2005;(1):CD005180.

[15] Derry S, Wiffen PJ, Moore RA, McNicol ED, Bell RF, Carr DB, et al. Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults. Cochrane Database Syst Rev. 2017;7(7):CD012638.

[16] Nabal M, Librada S, Redondo MJ, Pigni A, Brunelli C, Caraceni A. The role of paracetamol and nonsteroidal anti-inflammatory drugs in addition to WHO Step III opioids in the control of pain in advanced cancer. A systematic review of the literature. Palliat Med. 2012;26(4):305-12.

[17] Bennett MI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med. 2011;25(5):553-9.

[18] Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-73.

[19] Caraceni A, Zecca E, Bonezzi C, Arcuri E, Yaya Tur R, Maltoni M, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol. 2004;22(14):2909-17.

[20] Mishra S, Bhatnagar S, Goyal GN, Rana SP, Upadhya SP. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Care. 2012;29(3):177-82.

[21] Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20(8):1420-33.

[22] Swarm RA, Abernethy AP, Anghelescu DL, Benedetti C, Buga S, Cleeland C, et al. Adult cancer pain. J Natl Compr Canc Netw. 2013;11(8):992-1022.

[23] Porta-Sales J, Nabal-Vicuna M, Vallano A, Espinosa J, Planas-Domingo J, Verger-Fransoy E, et al. Have we improved pain control in cancer patients? A multicenter study of ambulatory and hospitalized cancer patients. J Palliat Med. 2015;18(11):923-32.

[24] Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994;330(9):592-6.

[25] Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol. 2008;19(12):1985-91.

[26] Oldenmenger WH, Sillevis Smitt PA, van Dooren S, Stoter G, van der Rijt CC. A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: a critical appraisal. Eur J Cancer. 2009;45(8):1370-80.

[27] Kwon JH. Overcoming barriers in cancer pain management. J Clin Oncol. 2014;32(16):1727-33.

[28] Gibbins J, Bhatia R, Forbes K, Reid CM. What do patients with advanced incurable cancer want from the management of their pain? A qualitative study. Palliat Med. 2014;28(1):71-8.

[29] Sun V, Borneman T, Piper B, Koczywas M, Ferrell B. Barriers to pain assessment and management in cancer survivorship. J Cancer Surviv. 2008;2(1):65-71.

[30] Jacobsen R, Møldrup C, Christrup L, Sjøgren P. Patient-related barriers to cancer pain management: a systematic exploratory review. Scand J Caring Sci. 2009;23(1):190-208.

[31] Ward SE, Goldberg N, Miller-McCauley V, Mueller C, Nolan A, Pawlik-Plank D, et al. Patient-related barriers to management of cancer pain. Pain. 1993;52(3):319-24.

[32] Gunnarsdottir S, Donovan HS, Serlin RC, Voge C, Ward S. Patient-related barriers to pain management: the Barriers Questionnaire II (BQ-II). Pain. 2002;99(3):385-96.

[33] Luckett T, Davidson PM, Green A, Boyle F, Stubbs J, Lovell M. Assessment and management of adult cancer pain: a systematic review and synthesis of recent qualitative studies aimed at developing insights for managing barriers and optimizing facilitators within a comprehensive framework of patient care. J Pain Symptom Manage. 2013;46(2):229-53.

[34] Hui D, Bruera E. A personalized approach to assessing and managing pain in patients with cancer. J Clin Oncol. 2014;32(16):1640-6.

[35] Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, et al. Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011;41(6):1073-93.

[36] Caraceni A, Cherny N, Fainsinger R, Kaasa S, Poulain P, Radbruch L, et al. Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage. 2002;23(3):239-55.

[37] Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994;23(2):129-38.

[38] Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983;17(2):197-210.

[39] Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;1(3):277-99.

[40] Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain. 2005;6(3):149-58.

[41] Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114(1-2):29-36.

[42] Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22(10):1911-20.

[43] Hagen NA, Stiles C, Nekolaichuk C, Biondo P, Carlson LE, Fisher K, et al. The Alberta Breakthrough Pain Assessment Tool for cancer patients: a validation study using a delphi process and patient think-aloud interviews. J Pain Symptom Manage. 2008;35(2):136-52.

[44] Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13(4):331-8.

[45] Caraceni A, Martini C, Zecca E, Portenoy RK, Ashby MA, Hawson G, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18(3):177-83.

[46] Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41(3):273-81.

[47] Davies A, Buchanan A, Zeppetella G, Porta-Sales J, Likar R, Weismayr W, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage. 2013;46(5):619-28.

[48] Mercadante S, Marchetti P, Cuomo A, Caraceni A, Mediati RD, Vellucci R, et al. Factors influencing the clinical presentation of breakthrough pain in cancer patients. Cancers (Basel). 2018;10(6):175.

[49] Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer. 2002;94(3):832-9.

[50] Zeppetella G, Davies AN. Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev. 2013;(10):CD004311.

[51] Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage. 2013;46(4):573-80.

[52] Mercadante S, Portenoy RK. Breakthrough cancer pain: twenty-five years of study. Pain. 2016;157(12):2657-63.

[53] Fallon M, Russo D, Banerjee S. How to manage breakthrough cancer pain and its impact on quality of life. ESC Perspect Med. 2019;7(1):28-36.

[54] Smith HS. Painful boney metastases. Ann Palliat Med. 2012;1(1):14-31.

[55] Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s-9s.

[56] von Moos R, Costa L, Gonzalez-Suarez E, Terpos E, Niepel D, Body JJ. Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody. Cancer Treat Rev. 2019;76:57-67.

[57] Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69(1-2):1-18.

[58] Mantyh PW. Mechanisms of malignant bone pain. Pain. 2013;154 Suppl 1:S54-62.

[59] Falk S, Dickenson AH. Pain and nociception: mechanisms of cancer-induced bone pain. J Clin Oncol. 2014;32(16):1647-54.

[60] Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer. 2013;119(4):832-8.

[61] Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-9.

[62] Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813-22.

[63] Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125-32.

[64] Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol). 2012;24(2):112-24.

[65] Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;79(4):965-76.

[66] Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol. 2007;25(11):1423-36.

[67] Rief H, Welzel T, Omlor G, Akbar M, Bruckner T, Rieken S, et al. Pain response of resistance training of the paravertebral musculature under radiotherapy in patients with spinal bone metastases--a randomized trial. BMC Cancer. 2014;14:485.

[68] Tharmalingam S, Chow E, Harris K, Hird A, Sinclair E. Quality of life measurement in bone metastases: A literature review. J Pain Res. 2008;1:49-58.

[69] McDonald R, Ding K, Brundage M, Meyer RM, Nabid A, Chabot P, et al. Effect of radiotherapy on painful bone metastases: a secondary analysis of the NCIC Clinical Trials Group Symptom Control Trial SC.23. JAMA Oncol. 2017;3(7):953-9.

[70] Chow R, Hoskin P, Hollenberg D, Lam M, Dennis K, Lutz S, et al. Efficacy of single fraction conventional radiation therapy for painful uncomplicated bone metastases: a systematic review and meta-analysis. Ann Palliat Med. 2017;6(2):125-42.

[71] Lu W, Rosenthal DS. Acupuncture for cancer pain and related symptoms. Curr Pain Headache Rep. 2013;17(3):321.

[72] Chiu HY, Hsieh YJ, Tsai PS. Systematic review and meta-analysis of acupuncture to reduce cancer-related pain. Eur J Cancer Care (Engl). 2017;26(2):e12457.

[73] Mao JJ, Xie SX, Farrar JT, Stricker CT, Bowman MA, Bruner D, et al. A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use. Eur J Cancer. 2014;50(2):267-76.

[74] He Y, Guo X, May BH, Zhang AL, Liu Y, Lu C, et al. Clinical evidence for association of acupuncture and acupressure with improved cancer pain: a systematic review and meta-analysis. JAMA Oncol. 2020;6(2):271-8.

[75] Deng G. Integrative medicine therapies for pain management in cancer patients. Cancer J. 2019;25(5):343-8.

[76] Zhang J, Xu R, Wang B, Wang J. Effects of mindfulness-based therapy for patients with breast cancer: A systematic review and meta-analysis. Complement Ther Med. 2016;26:1-10.

[77] Charalambous A, Giannakopoulou M, Bozas E, Paikousis L. A randomized controlled trial for the effectiveness of progressive muscle relaxation and guided imagery as anxiety reducing interventions in breast and prostate cancer patients undergoing chemotherapy. Evid Based Complement Alternat Med. 2015;2015:270876.

[78] Özveren H, Uçar H. The effects of progressive muscle relaxation on the management of fatigue and quality of sleep in cancer patients undergoing chemotherapy. Eur J Oncol Nurs. 2020;46:101748.

[79] Cramer H, Lauche R, Paul A, Langhorst J, Kümmel S, Dobos GJ. Hypnosis in breast cancer care: a systematic review of randomized controlled trials. Integr Cancer Ther. 2015;14(1):5-15.

[80] Syrjala KL, Jensen MP, Mendoza ME, Yi JC, Fisher HM, Keefe FJ. Psychological and behavioral approaches to cancer pain management. J Clin Oncol. 2014;32(16):1703-11.

[81] Stubblefield MD, Keole N. Upper body pain and functional disorders in patients with breast cancer. PM R. 2014;6(2):170-83.

[82] Nakano J, Hashizume K, Fukushima T, Ueno K, Matsuura E, Ikio Y, et al. Effects of aerobic and resistance exercises on physical symptoms in cancer patients: a meta-analysis. Integr Cancer Ther. 2018;17(4):1048-58.

[83] Cantarero-Villanueva I, Fernández-Lao C, Fernández-de-Las-Peñas C, López-Barajas IB, Del-Moral-Ávila R, de la-Llave-Rincón AI, et al. Effectiveness of water physical therapy on pain, pressure pain sensitivity, and myofascial trigger points in breast cancer survivors: a randomized, controlled clinical trial. Pain Med. 2012;13(11):1509-19.

[84] Hurlow A, Bennett MI, Robb KA, Johnson MI, Simpson KH, Oxberry SG. Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults. Cochrane Database Syst Rev. 2012;(3):CD006276.

[85] Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA. 1995;274(23):1870-3.

[86] Sundararaman LV, Edwards RR, Ross EL, Jamison RN. Integration of mobile health technology in the treatment of chronic pain: a critical review. Reg Anesth Pain Med. 2017;42(4):488-98.

[87] Jonassaint CR, Shah N, Jonassaint J, De Castro L. Usability and feasibility of an mHealth intervention for monitoring and managing pain symptoms in sickle cell disease: the Sickle Cell Disease Mobile Application to Record Symptoms via Technology (SMART). Hemoglobin. 2015;39(3):162-8.

[88] Mack J, Snelling B, Wilson S, McGrath P. Technology in pediatric pain management. Semin Pediatr Neurol. 2016;23(3):220-31.

[89] Meijer F, Honing M, Roor T, Toet S, Calis P, Olofsen E, et al. Reduced postoperative pain using Nociception Level-guided fentanyl dosing during sevoflurane anaesthesia: a randomised controlled trial. Br J Anaesth. 2020;125(6):1070-8.

[90] Huang HY, Lin YS, Chuang YC, Lin HW, Huang JJ, Chen SC, et al. Application of wearable sensors for pain assessment in patients with lung cancer: A feasibility study. J Clin Med. 2021;10(4):593.

[91] Darnall BD, Krishnamurthy P, Tsuei J, Minor JD. Self-administered skills-based virtual reality intervention for chronic pain: randomized controlled pilot study. JMIR Form Res. 2020;4(7):e17293.